Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

K. Muro; F. Lordick; T. Tsushima; G. Pentheroudakis; E. Baba; Z. Lu; B. C. Cho; I. M. Nor; M. Ng; L. T. Chen; K. Kato; J. Li; M. H. Ryu; W. I. Wan Zamaniah; W. P. Yong; K. H. Yeh; T. E. Nakajima; K. Shitara; H. Kawakami; Y. Narita; T. Yoshino; E. Van Cutsem; E. Martinelli; E. C. Smyth; D. Arnold; H. Minami; J. Tabernero; J. Y. Douillard

doi:10.1093/annonc/mdy498

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

K. Muro, F. Lordick, T. Tsushima, G. Pentheroudakis, E. Baba, Z. Lu, B. C. Cho, I. M. Nor, M. Ng, L. T. Chen, K. Kato, J. Li, M. H. Ryu, W. I. Wan Zamaniah, W. P. Yong, K. H. Yeh, T. E. Nakajima, K. Shitara, H. Kawakami, Y. NaritaT. Yoshino, E. Van Cutsem, E. Martinelli, E. C. Smyth, D. Arnold, H. Minami, J. Tabernero, J. Y. Douillard

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

77 Citations (Scopus)

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

Original language	English
Pages (from-to)	34-43
Number of pages	10
Journal	Annals of Oncology
Volume	30
Issue number	1
DOIs	https://doi.org/10.1093/annonc/mdy498
Publication status	Published - 2019 Jan 1

Bibliographical note

Funding Information:
The authors would like to thank Ms C. Tada from the secretariat of JSMO and Ms K. Marinoni, ESMO Assistant, for their preparation and on-site assistance and support during the face-to-face meeting of experts in Kobe. Dr A. Kinsella, Cancer Communications and Consultancy Ltd, Knutsford, Cheshire, UK is acknowledged for her assistance in the preparation of the manuscript funded by JSMO.

Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

All Science Journal Classification (ASJC) codes

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy498

Cite this

Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B. C., Nor, I. M., Ng, M., Chen, L. T., Kato, K., Li, J., Ryu, M. H., Wan Zamaniah, W. I., Yong, W. P., Yeh, K. H., Nakajima, T. E., Shitara, K., Kawakami, H., ... Douillard, J. Y. (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology, 30(1), 34-43. https://doi.org/10.1093/annonc/mdy498

@article{9280be8cc39a439d8dde0e13da6de731,

title = "Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS",

abstract = "The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.",

author = "K. Muro and F. Lordick and T. Tsushima and G. Pentheroudakis and E. Baba and Z. Lu and Cho, {B. C.} and Nor, {I. M.} and M. Ng and Chen, {L. T.} and K. Kato and J. Li and Ryu, {M. H.} and {Wan Zamaniah}, {W. I.} and Yong, {W. P.} and Yeh, {K. H.} and Nakajima, {T. E.} and K. Shitara and H. Kawakami and Y. Narita and T. Yoshino and {Van Cutsem}, E. and E. Martinelli and Smyth, {E. C.} and D. Arnold and H. Minami and J. Tabernero and Douillard, {J. Y.}",

note = "Funding Information: The authors would like to thank Ms C. Tada from the secretariat of JSMO and Ms K. Marinoni, ESMO Assistant, for their preparation and on-site assistance and support during the face-to-face meeting of experts in Kobe. Dr A. Kinsella, Cancer Communications and Consultancy Ltd, Knutsford, Cheshire, UK is acknowledged for her assistance in the preparation of the manuscript funded by JSMO. Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.",

year = "2019",

month = jan,

day = "1",

doi = "10.1093/annonc/mdy498",

language = "English",

volume = "30",

pages = "34--43",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "1",

}

Muro, K, Lordick, F, Tsushima, T, Pentheroudakis, G, Baba, E, Lu, Z, Cho, BC, Nor, IM, Ng, M, Chen, LT, Kato, K, Li, J, Ryu, MH, Wan Zamaniah, WI, Yong, WP, Yeh, KH, Nakajima, TE, Shitara, K, Kawakami, H, Narita, Y, Yoshino, T, Van Cutsem, E, Martinelli, E, Smyth, EC, Arnold, D, Minami, H, Tabernero, J & Douillard, JY 2019, 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS', Annals of Oncology, vol. 30, no. 1, pp. 34-43. https://doi.org/10.1093/annonc/mdy498

TY - JOUR

T1 - Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer

T2 - A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

AU - Muro, K.

AU - Lordick, F.

AU - Tsushima, T.

AU - Pentheroudakis, G.

AU - Baba, E.

AU - Lu, Z.

AU - Cho, B. C.

AU - Nor, I. M.

AU - Ng, M.

AU - Chen, L. T.

AU - Kato, K.

AU - Li, J.

AU - Ryu, M. H.

AU - Wan Zamaniah, W. I.

AU - Yong, W. P.

AU - Yeh, K. H.

AU - Nakajima, T. E.

AU - Shitara, K.

AU - Kawakami, H.

AU - Narita, Y.

AU - Yoshino, T.

AU - Van Cutsem, E.

AU - Martinelli, E.

AU - Smyth, E. C.

AU - Arnold, D.

AU - Minami, H.

AU - Tabernero, J.

AU - Douillard, J. Y.

N1 - Funding Information: The authors would like to thank Ms C. Tada from the secretariat of JSMO and Ms K. Marinoni, ESMO Assistant, for their preparation and on-site assistance and support during the face-to-face meeting of experts in Kobe. Dr A. Kinsella, Cancer Communications and Consultancy Ltd, Knutsford, Cheshire, UK is acknowledged for her assistance in the preparation of the manuscript funded by JSMO. Publisher Copyright: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

AB - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

UR - http://www.scopus.com/inward/record.url?scp=85060182066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060182066&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy498

DO - 10.1093/annonc/mdy498

M3 - Article

C2 - 30475943

AN - SCOPUS:85060182066

SN - 0923-7534

VL - 30

SP - 34

EP - 43

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this